ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
AstraZeneca is working with the life sciences investment firm Nomura Phase4 Ventures to spin off a number of its gastrointestinal (GI) drug programs. The result will be a new company called Albireo, based in Gothenburg, Sweden. Nomura Phase4 and other investors have raised $27 million and expect to raise another $40 million to fund the company. AstraZeneca earlier decided to concentrate only on GI research for gastroesophageal reflux disease.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X